A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study
一项评估利博西尼联合来曲唑作为一线治疗方案在激素受体阳性、HER2阴性晚期乳腺癌老年女性（≥70岁）中疗效和安全性的IV期前瞻性研究：RibOB研究
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105896
Van Houdt, M; Kenis, C; De Nys, L; Hatse, S; Neven, P; Laenen, A; Mebis, J; de Azambuja, E; Ponde, N F; Decoster, L; Quaghebeur, C; Cornelis, F; Verhoeven, D M E C; Barbeaux, A; Verschaeve, V; Wildiers, H
